Tag: Okays

Neurology

FDA Okays Cenobamate (Xcopri) for Focal Epilepsy

Newsemia
The FDA has approved cenobamate for seizures in adults with focal epilepsy based on results from two trials of more than 600 patients, as well...
Neurology

FDA Okays Pitolisant (Wakix) for Narcolepsy

Newsemia
The FDA has approved pitolisant, a first-in-class, nonscheduled treatment option with a novel mechanism of action for adults with narcolepsy. FDA Approvals Source link...
Neurology

FDA Okays First Generic Naloxone Nasal Spray for Opioid Overdose

Newsemia
The FDA has granted final approval for the first generic naloxone hydrochloride nasal spray for reversing or stopping the effects from an opioid overdose. FDA...
Neurology

FDA Okays Pipeline Device for Small, Medium Brain Aneurysms

Newsemia
The extended indication for the device is based on results from the PREMIER trial. It is already approved for large or giant wide-necked intracranial aneurysms....
Neurology

FDA Okays Rivaroxaban Plus Aspirin for Chronic CAD, PAD

Newsemia
The rivaroxaban/aspirin combination is for the prevention of thrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk for...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World